Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
- Overview
- Key stats
- Stock price
- Financial performance
- Price vs fundamentals
- Growth
- Valuations
- Efficiency
- Dividends
- Financial health
- Stocks
- Healthcare
- NASDAQ: SCYX
Price (delayed)
$0.9573
Market cap
$37.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$36.99M
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly ...
Highlights
Scynexis's gross margin has increased by 12% YoY
The gross profit has soared by 161% QoQ but it has shrunk by 97% YoY
The company's net income has shrunk by 132% YoY but it rose by 42% QoQ
Scynexis's revenue has shrunk by 97% YoY and by 56% QoQ
Scynexis's quick ratio has shrunk by 51% YoY and by 5% QoQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.scynexis.com
Peers: CPRX
Key stats
What are the main financial stats of SCYX
MarketValuationsEarnings
Shares outstanding
38.98M
Market cap
$37.32M
Enterprise value
$36.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
12.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.87
Revenue
$3.75M
Gross profit
$3.75M
Operating income
-$37.12M
Net income
-$21.29M
EBIT
-$20.31M
EBITDA
-$20.31M
Free cash flow
-$24.01M
Per shareBalance sheetLiquidity
EPS
-$0.44
EPS diluted
-$0.44
Free cash flow per share
-$0.49
Book value per share
$1.45
Revenue per share
$0.08
TBVPS
$1.87
Total assets
$90.64M
Total liabilities
$35.57M
Debt
$16.27M
Equity
$55.08M
Working capital
$48.08M
Debt to equity
0.3
Current ratio
3
Quick ratio
2.91
Net debt/EBITDA
0.02
MarginsEfficiencyDividend
EBITDA margin
-542.2%
Gross margin
100%
Net margin
-568.3%
Operating margin
-990.8%
Return on assets
-20.5%
Return on equity
-34.3%
Return on invested capital
-30.3%
Return on capital employed
-30.5%
Return on sales
-542.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCYX stock price
How has the Scynexis stock price performed over time
Intraday
-0.41%
1 week
-2.53%
1 month
19.02%
1 year
-47.97%
YTD
-20.88%
QTD
0.55%
Financial performance
How have Scynexis's revenue and profit performed over time
Revenue
$3.75M
Gross profit
$3.75M
Operating income
-$37.12M
Net income
-$21.29M
Gross margin
100%
Net margin
-568.3%
SCYX financials
The gross profit has soared by 161% QoQ but it has shrunk by 97% YoY
SCYX's operating income has shrunk by 151% YoY but it is up by 29% QoQ
The company's net income has shrunk by 132% YoY but it rose by 42% QoQ
Scynexis's revenue has shrunk by 97% YoY and by 56% QoQ
Price vs fundamentals
How does SCYX's price correlate with its fundamentals
Price vs fundamentals
Earnings waterfall
Growth
What is Scynexis's growth rate over time
SCYX growth chart
Valuation
What is Scynexis stock price valuation
P/E
N/A
P/B
0.66
P/S
12.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.87
Valuation vs average
Price to earnings (P/E)
The company's EPS has shrunk by 131% YoY but it rose by 42% QoQ
Price to book (P/B)
SCYX's price to book (P/B) is 83% lower than its 5-year quarterly average of 3.9 and 27% lower than its last 4 quarters average of 0.9
The equity has declined by 25% year-on-year and by 6% since the previous quarter
Price to sales (P/S)
Scynexis's revenue has shrunk by 97% YoY and by 56% QoQ
The P/S is 43% higher than the last 4 quarters average of 8.7 but 23% lower than the 5-year quarterly average of 16.0
Efficiency
How efficient is Scynexis business performance
Scynexis's return on assets has shrunk by 138% YoY but it has increased by 36% QoQ
SCYX's return on invested capital has dropped by 136% year-on-year but it is up by 37% since the previous quarter
The return on equity has dropped by 129% year-on-year but it has increased by 37% since the previous quarter
The company's return on sales fell by 31% QoQ
Dividends
What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCYX.
Financial health
How did Scynexis financials performed over time
Assets vs liabilities
The total assets is 155% more than the total liabilities
The current ratio has plunged by 52% YoY and by 4.2% from the previous quarter
Scynexis's quick ratio has shrunk by 51% YoY and by 5% QoQ
Debt vs equity
Scynexis's debt is 70% less than its equity
The company's debt to equity rose by 43% YoY and by 11% QoQ
The equity has declined by 25% year-on-year and by 6% since the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.